Table 1. Available data sets.

EPO	chemotherapy	disease	reference
Alfa	none	none	[33]
Alfa	none	none	[60]
Alfa	none	none	[61]
Alfa	none	none	[62]
Alfa	none	none	[54]
Alfa	none	none	[31]
Alfa	none	none	[63]
Alfa	none	none	[64]
Beta	none	none	[55]
Beta	none	none	[32]
Beta	none	none	[56]
Beta	none	none	[26]
Beta	none	none	[25]
Delta	none	none	[27]
Darbepoetin Alfa	none	none	[58]
Alfa	E-T-C	breast cancer	[65]
Darbepoetin Alfa	Platinum,	Small-Cell	[59]
	Etoposide-21	Lung Cancer
none	Platinum,	Small-Cell	[59]
	Etoposide-21	Lung Cancer
none	CHOP-21*	NHL	[15], [16]
none	CHOEP-21*	NHL	[15], [16]
none	BEACOPP-21*	HD	[19]
none	CHOP-14*	NHL	[15], [16]
none	CHOP-14*	NHL	[18]
none	CHOEP-14*	NHL	[15], [16]
none	high-	NHL	[17]
	CHOEP-21*
none	BEACOPP-14*	HD	[20]
none	BEACOPP -21	HD	[19]
	escalated*
none	E-T-C	breast cancer	[65]
none	EC-T	breast cancer	[65]

Upper part: Data sets regarding application of different EPO derivatives in healthy volunteers. Lower part: Chemotherapy data sets, those with access to raw data are indicated with an asterisk. HD = Hodgkin's disease, NHL = aggressive non-Hodgkin lymphoma.